Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
VRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.39 - $70.40
Previous CloseN/A
Volume658.49K
Average Volume (3M)1.41M
Market Cap
$5.65B
Enterprise Value$2.23B
Total Cash (Recent Filing)$399.76M
Total Debt (Recent Filing)$122.70M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Apr 30, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding79,110,640
10 Day Avg. Volume1,251,085
30 Day Avg. Volume1,406,809
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)134.29
Price to Cash Flow (P/CF)-49.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit56.25
Enterprise Value/Ebitda-17.73
Forecast
1Y Price Target
$80.29Price Target Upside20.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionPartnership plan on territory expansion for Ohtuvayre in the EU and the UK.
Product InnovationOhtuvayre's unique bronchodilator and anti-inflammatory mechanism will drive robust growth.
Revenue GrowthOhtuvayre's net revenue during 4Q24 was approximately three times higher than the initial estimate.
Bears Say
Patent ExpirationThe company may be able to patent the effect of Ohtuvayre due to the co-inhibition of PDE4 and PDE3, which could extend the drug's protection by at least five-plus years.
Pricing PressureA 25% cut in pricing is modeled in 2033 due to the Inflation Reduction Act, and a 40% price cut in 2036 due to patent expiration.
---
Ownership Overview
42.79% Insiders
12.62% Mutual Funds
0.25% Other Institutional Investors
43.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRNA FAQ
What was Verona Pharma Plc’s price range in the past 12 months?
Verona Pharma Plc lowest stock price was $11.39 and its highest was $70.40 in the past 12 months.
What is Verona Pharma Plc’s market cap?
Verona Pharma Plc’s market cap is $5.65B.
When is Verona Pharma Plc’s upcoming earnings report date?
Verona Pharma Plc’s upcoming earnings report date is Apr 30, 2025 which is in 35 days.
How were Verona Pharma Plc’s earnings last quarter?
Verona Pharma Plc released its earnings results on Feb 27, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.022.
Is Verona Pharma Plc overvalued?
According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued.
Does Verona Pharma Plc pay dividends?
Verona Pharma Plc does not currently pay dividends.
What is Verona Pharma Plc’s EPS estimate?
Verona Pharma Plc’s EPS estimate is -0.07.
How many shares outstanding does Verona Pharma Plc have?
Verona Pharma Plc has 79,110,640 shares outstanding.
What happened to Verona Pharma Plc’s price movement after its last earnings report?
Verona Pharma Plc reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went up 5.668%.
Which hedge fund is a major shareholder of Verona Pharma Plc?
Currently, no hedge funds are holding shares in VRNA
---
Verona Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.29 (20.23% Upside)
$80.29 (20.23% Upside)
Blogger Sentiment
Bearish
VRNA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $88.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
315.55%
12-Months-Change
Fundamentals
Return on Equity
-76.51%
Trailing 12-Months
Asset Growth
53.91%
Trailing 12-Months
Company Description
Verona Pharma Plc
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
---
VRNA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, driven by the successful launch and strong initial sales of O2VARE, significant prescriber adoption, and strategic global expansion efforts. However, increased costs and losses and some challenges with reimbursement are noted as areas of concern.Read More>---
VRNA Stock 12 Month Forecast
Average Price Target
$80.29
▲(20.23% Upside)
Technical Analysis
Best Analysts Covering VRNA
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+153.96%
reiterated a buy rating 27 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +153.96% per trade.
---